EP 162:51

Your brain on a GLP-1: food noise, cravings and alcohol

Name: Your brain on a GLP-1: food noise, cravings and alcohol
Uploaded: 2026-09-28
Duration: 2 min 51 s
Description: Why people describe food noise going quiet: where GLP-1 drugs act in the brain, a recording from one person's reward hub, the appetite and brain-scan studies, the early alcohol trials, and what is still unknown.

Why people describe food noise going quiet: where GLP-1 drugs act in the brain, a recording from one person's reward hub, the appetite and brain-scan studies, the early alcohol trials, and what is still unknown.

Transcript and sources

Scientists recorded food noise inside one person's brain. On a GLP-1, it went quiet, and months later, it came back.
Food noise isn't a medical term. It's a popular phrase for constant, intrusive thoughts about food. In a 2026 survey, about half of US adults said they experience it at least sometimes.
That recording came from one person with electrodes in the brain's reward hub, the nucleus accumbens. On tirzepatide, the food preoccupation went quiet, then broke through again months later. It's one person, but it's a rare look inside.
GLP-1 receptors have been found on neurons in the human hypothalamus and hindbrain. In mice and rats, semaglutide didn't cross the blood-brain barrier; it reached the brain through a few leaky spots.
In rats, GLP-1-making cells in the hindbrain wire straight into the brain's reward circuit, and triggering GLP-1 receptors there cut both sugar-seeking and alcohol drinking.
In people, it shows up on the plate. In a twenty-week trial, people on semaglutide ate thirty-five percent less at a free-choice lunch and reported fewer, weaker cravings.
In brain scans, a GLP-1 drug lowered responses to food pictures in reward-related areas, and blocking the receptor largely stopped that.
Then, alcohol. In a forty-eight-person trial, low-dose semaglutide cut how much people drank in a lab session and reduced craving, though it didn't change how many days they drank. And in a 2026 trial of a hundred and eight people with alcohol use disorder and obesity, it cut heavy drinking days by about fourteen percentage points more than placebo.
In Swedish records of two hundred and twenty-seven thousand people with alcohol use disorder, periods on semaglutide had thirty-six percent fewer alcohol hospitalizations. That's observational: it shows a link, not proof.
Not every craving moves the same way. In a small smoking trial, semaglutide eased cravings but didn't cut cigarettes.
No GLP-1 drug is approved to treat alcohol, nicotine or any other addiction. A six-hundred-and-twenty-two-person trial for alcohol started in July 2026, with results expected around 2029. And researchers still don't know how much of this is the brain itself, and how much is weight loss or nausea.
It's not just your stomach, it's your brain, and science is only starting to map it. Every study is at peplexicon.com.

Sources